Amarin ($AMRN)
Market cap: $1.68 billion

Soon after new AstraZeneca ($AZN) CEO Pascal Soriot hit the brakes on the pharma company's multibillion-dollar stock buyback program, the Daily Mail fanned rumors that he was looking at a possible bid for Amarin, which holds the rights to the newly approved Vascepa, an industrial-strength omega 3 fish-oil therapy that has been crawling to the market at a snail's pace.

Of course, once buyout fever hits a company, there's no end to the list of possible bidders. And many of the usual suspects--Pfizer ($PFE), Merck ($MRK), Abbott ($ABT)--have been linked to one not-so-usual suspect: Eli Lilly ($LLY).

Vascepa is intended to help out the cardiovascular crowd, a vast market that requires big-market sales ability that Amarin clearly doesn't have and can't simply recruit. The competitor in the field is GlaxoSmithKline ($GSK), which markets Lovaza with about $1 billion in annual sales.

But some analysts--led by TheStreet's Adam Feuerstein--have been waiting quite some time to hear whether Vascepa will earn new chemical entity (NCE) status, which could prove key to guarding against near-term generic competition that would wipe out much of its value. As long as a cloud is hanging over its value, investors will continue to speculate endlessly about a possible takeover and the ultimate reward they could expect from a winning bid. But if Amarin fails to win NCE status and goes ahead with a weak solo launch, these rumors could melt away quickly under the heat of a sudden attitude adjustment.

For more:
Omthera trumpets PhIII success for Omega-3 rival to Amarin's Vascepa
Is AstraZeneca angling for a blockbuster Amarin buyout?
Another NCE delay for Amarin takes a bite out of its share price


Suggested Articles

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial. 

The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.